Zobrazeno 1 - 10
of 398
pro vyhledávání: '"Third-line therapy"'
Autor:
Jingjing Duan, Lila Zhu, Yinghui Shi, Weixue Wang, Tongtong Wang, Tao Ning, Le Zhang, Ming Bai, Hongli Li, Rui Liu, Shaohua Ge, Xia Wang, Yuchong Yang, Zhi Ji, Feixue Wang, Yansha Sun, Yi Ba, Ting Deng
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background There are various recommendations for third-line treatment in mCRC, however, there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use in third-line setting is a common option in clinical practice.
Externí odkaz:
https://doaj.org/article/a26596c14aa84753aa2edb267d7deebc
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 22038-22046 (2023)
Abstract Background Fruquintinib has demonstrated significant improvement in overall survival (OS) among previously treated metastatic colorectal cancer (mCRC) patients. However, the utilization of fruquintinib has been constrained by various toxicit
Externí odkaz:
https://doaj.org/article/dec86540cc4e4b57945818b50db56fa8
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 16, Iss 3, Pp 422-430 (2023)
Objective: to evaluate the pharmacoeconomic efficiency of atezolizumab (inhibitor of programmed death ligand 1 (PD-L1)) in comparison with other checkpoint inhibitors (inhibitors of programmed cell death protein 1 (PD-1)) in patients with advanced no
Externí odkaz:
https://doaj.org/article/5656c1d6fa50463293e6ecaf843b805f
Publikováno v:
Oncology and Therapy, Vol 11, Iss 4, Pp 495-511 (2023)
Abstract Introduction Patients with follicular lymphoma (FL) receiving third-line or later (3L +) therapy have long survival, which can make estimating long-term overall survival (OS) from trial data challenging. The objective of this study was to es
Externí odkaz:
https://doaj.org/article/1f1ad0384b1b41998012a03cb2c09506
Autor:
E. Gabriela Chiorean, Vincent Picozzi, Chung‐Pin Li, Marc Peeters, Joan Maurel, Jaswinder Singh, Talia Golan, Jean‐Frédéric Blanc, Sonya C. Chapman, Anwar M. Hussain, Erica L. Johnston, Howard S. Hochster
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20353-20364 (2023)
Abstract Background Pancreatic ductal adenocarcinomas (PDAC) are characterized by frequent cell cycle pathways aberrations. This study evaluated safety and efficacy of abemaciclib, a cyclin‐dependent kinase 4 and 6 inhibitor, as monotherapy or in c
Externí odkaz:
https://doaj.org/article/361cb4c885cb4edb9ee2ff88993a88f9
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 50, Iss 6, Pp 593-597 (2023)
Objective To investigate the clinical efficacy and related adverse reactions of the combination of camrelizumab with anlotinib as the third-line therapy on advanced non-small cell lung cancer. Methods We retrospectively analyzed the clinical data of
Externí odkaz:
https://doaj.org/article/582a2590887d440dbfbb3df07ce3ac96
Autor:
Carlo Signorelli, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, Cristina Morelli, Emanuela Dell’Aquila, Antonella Cosimati, Donatello Gemma, Marta Ribelli, Alessandra Emiliani, Domenico Cristiano Corsi, Giulia Arrivi, Federica Mazzuca, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Rosa Saltarelli, Enzo Maria Ruggeri
Publikováno v:
Current Oncology, Vol 30, Iss 6, Pp 5456-5469 (2023)
Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options with
Externí odkaz:
https://doaj.org/article/afc24ec0fba644d393d93c2ccdec9fdd
Publikováno v:
Systematic Reviews, Vol 11, Iss 1, Pp 1-17 (2022)
Abstract Background The World Health Organization (WHO) has identified the need for evidence on third-line antiretroviral therapy (ART) for adults living with HIV/AIDS, given that some controversy remains as to the best combinations of ART for experi
Externí odkaz:
https://doaj.org/article/4b229a325ec043e39907b59aced771be
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Oncology, Vol 29, Iss 9, Pp 6433-6444 (2022)
In recent years, advances of anticancer and supportive therapies have determined a gradual improvement in survival rates and patients’ general conditions in metastatic gastric cancer (mGC), allowing them to receive further treatments. The choice of
Externí odkaz:
https://doaj.org/article/ad9cdd23b88240ce9eb246d70c300412